HRT Implants vs Injections for Perimenopause: What Women Need to Know
Compare pellet HRT implants vs testosterone and oestradiol injections for perimenopause: dose control, UK and Australia availability, reversal, risks, and clinical use.
Beyond Patches and Gels: Understanding Long-Acting HRT Delivery
Most perimenopausal women receiving HRT use daily or twice-weekly transdermal preparations such as gels, patches, or sprays, which provide consistent hormone delivery and allow easy dose adjustment or discontinuation. However, two less commonly discussed long-acting delivery methods exist: subcutaneous pellet implants and injectable preparations. Both approaches aim to reduce the burden of daily or frequent administration and to maintain more stable serum hormone levels over weeks or months. For some women, the convenience appeal is significant. For others, the reduced flexibility and specific risk profiles make these options less suitable. Understanding how pellet implants and injections compare, where they are used, what they cannot do that patches and gels can, and what the clinical evidence says helps perimenopausal women engage in informed conversations with their prescribers about whether these routes are genuinely appropriate for their situation.
Pellet Implants: How They Work and Where They Are Used
Subcutaneous hormone pellets are small compressed cylinders of crystalline hormone (typically oestradiol, testosterone, or a combination) that are inserted under the skin, usually in the subcutaneous fat of the buttock or lower abdomen, using a local anaesthetic and a trocar. Once implanted, the pellet releases hormone continuously over three to six months as it slowly dissolves. The procedure takes around 15 minutes in a clinic setting and is minimally invasive. Pellet implants have been used in the UK since the 1930s, making them a genuinely long-established HRT delivery method. In Australia, they have also been available for decades through specialist menopause and endocrinology practices. Oestradiol pellets in the UK are typically dosed at 25 to 100 milligrams, inserted every four to six months. Testosterone pellets, while used in some private UK clinics, are more established in Australian and US practice. The key limitation of pellets is irreversibility: once implanted, the dose cannot be adjusted, and if side effects occur or the dose proves too high, the only management option is to wait for the pellet to dissolve.
Injectable HRT: Preparations and Clinical Applications
Injectable oestradiol preparations provide another route for women who cannot absorb transdermal products effectively or who require more stable levels than patches or gels reliably provide. In the UK, oestradiol valerate and oestradiol cypionate injectable preparations have been used, though they are far less commonly prescribed than in some other countries and are not part of mainstream NHS formulary practice. Testosterone injections (such as testosterone cypionate or testosterone undecanoate) are used off-label for women in both the UK and Australia, typically by endocrinologists or specialist menopause practitioners managing testosterone deficiency. Injectable testosterone at female doses offers depot delivery with an injection interval of two to four weeks depending on the preparation. The advantage over pellets is slightly more dose control (you can stop injecting if problems arise) and no minor surgical procedure. The disadvantage is the need for regular injections and the potential for troughs in hormone levels in the days before the next injection is due, which some women find symptomatically significant.
Dose Control and Reversal: A Critical Safety Consideration
The reversibility question separates implants and injections from standard transdermal HRT in a clinically important way. With a patch, gel, or spray, dose adjustment is immediate: use a lower dose patch, apply less gel, or stop altogether if a problem arises. With injections, you can stop the injection schedule and allow depot hormone levels to fall, typically over two to four weeks depending on the compound. With pellets, you have no dose adjustment option whatsoever until the pellet dissolves, which takes three to six months. If a pellet dose is too high, causing symptoms such as acne, mood changes, elevated haematocrit, breast discomfort, or in the case of testosterone, virilising effects, the woman must simply manage the side effects and wait. This irreversibility makes accurate initial dosing critical, and it is why many menopause specialists who have broad formulary access prefer transdermal preparations for most patients, reserving pellets for those with specific absorption or adherence challenges. The risk of supraphysiological levels, particularly with testosterone pellets, is a documented concern associated with pellet use.
Availability and Prescribing Context in the UK and Australia
In the UK, oestradiol pellet implants are available but predominantly through private specialist clinics. They are not part of standard NHS HRT provision. The NHS does include subcutaneous implants in its prescribing framework historically, but in practice, they are uncommon in NHS settings and most commonly accessed privately at specialist menopause clinics. Testosterone pellets are even less commonly available in UK clinical practice, with most UK specialists preferring AndroFeme cream or off-label Testogel for female testosterone supplementation. In Australia, hormone pellet therapy is similarly a private sector treatment offered by some specialist practitioners, with variable quality control and dosing standards across different clinics. Injectable testosterone for women in Australia is more established through compounding pharmacies, where testosterone propionate, cypionate, or undecanoate can be prepared in female-appropriate doses under prescription. The absence of a standardised, widely approved injectable testosterone product specifically for women in both countries means the compounding pharmacy route is required, adding complexity and cost.
Who Might Benefit and What to Discuss with Your Prescriber
Pellet implants are most appropriate for women who have documented poor absorption from transdermal preparations (confirmed by blood tests showing inadequate hormone levels despite appropriate transdermal dosing), who have severe adherence challenges with daily or twice-weekly applications, or who have experienced inadequate symptom control despite optimised transdermal regimens. They are not a first-line approach and should only be used by prescribers with significant experience in hormone pellet dosing for women, given the irreversibility risk. Injectable preparations may suit women in similar situations or those who prefer monthly clinical contact and monitoring as part of their care. If you are considering either approach, ask your prescriber to explain the monitoring protocol (blood levels should be checked at appropriate intervals), what the management plan is if your levels run too high, how they determine the appropriate starting dose, and their experience with this delivery method specifically in women. Both approaches are legitimate options within specialist practice, but the broader and more accessible formulary of transdermal preparations remains the recommended starting point for most perimenopausal women seeking HRT.
Related reading
Get your personalized daily plan
Track symptoms, match workouts to your day type, and build a routine that adapts with you through every phase of perimenopause.